Low dose intranasal oxytocin delivered with Breath Powered device dampens amygdala response to emotional stimuli: A peripheral effect-controlled within-subjects randomized dose-response fMRI trial  by Quintana, Daniel S. et al.
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It is unclear  if and  how  exogenous  oxytocin  (OT)  reaches  the brain  to improve  social  behavior  and  cogni-
tion  and  what  is  the  optimal  dose  for  OT response.  To  better  understand  the delivery  routes  of  intranasal
OT  administration  to the  brain  and  the  dose-response,  we  compared  amygdala  response  to facial  stim-
uli  by  means  of functional  magnetic  resonance  imaging  (fMRI)  in  four  treatment  conditions,  including
two  different  doses  of  intranasal  OT using  a novel  Breath  Powered  device,  intravenous  (IV)  OT,  which
provided  similar  concentrations  of  blood  plasma  OT,  and  placebo.  We  adopted  a randomized,  double-
blind,  double-dummy,  crossover  design,  with  16  healthy  male  adults  administering  a  single-dose  of  these
four  treatments.  We  observed  a  treatment  effect  on  right  amygdala  activation  during  the  processing  of
angry  and  happy  face  stimuli,  with  pairwise  comparisons  revealing  reduced  activation  after  the  8IU  lowMRI dose intranasal  treatment  compared  to placebo.  These  data  suggest  the dampening  of amygdala  activity
in response  to emotional  stimuli  occurs  via  direct  intranasal  delivery  pathways  rather  than  across  the
blood-brain  barrier  via  systemically  circulating  OT.
Trial  registration:  This  trial  is  registered  at the U.S.  National  Institutes  of  Health  clinical  trial  registry
(www.clinicaltrials.gov; NCT01983514)  and  as EudraCT  no.  2013-001608-12.
ublis© 2016  The  Authors.  P
. Introduction
A conﬂuence of research indicates that oxytocin (OT) plays an
mportant role in regulating social cognition and behavior in both
nimals and humans. For example, intranasal administration of OT
mproves the accuracy of social information appraisal, the encod-
ng of social memories, and the retrieval of social cues (Guastella
nd MacLeod, 2012). Converging evidence suggesting that OT may
mprove social cognition has contributed to its proposed use as a
∗ Corresponding author at: NORMENT, KG Jebsen Centre for Psychosis Research,
uilding 49, Oslo University Hospital, Ullevål, Kirkeveien 166, PO Box 4956 Nydalen,
-0424 Oslo, Norway.
E-mail address: o.a.andreassen@medisin.uio.no (O.A. Andreassen).
ttp://dx.doi.org/10.1016/j.psyneuen.2016.04.010
306-4530/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article 
/).hed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
novel treatment for disorders characterized by social impairments,
such as autism spectrum disorders (ASD; Guastella et al., 2010;
Yatawara et al., 2015), schizophrenia spectrum disorders (Davis
et al., 2013; Guastella et al., 2015), anxiety disorders (Frijling et al.,
2016; Koch et al., 2014; Labuschagne et al., 2010), and substance
dependence (McRae-Clark et al., 2013). This interest has also led to
an increasing number of clinical trials evaluating the efﬁcacy of OT
treatment for a range of neuropsychiatric disorders (for a review,
see Quintana et al., 2016). Nevertheless, there are two barriers hin-
dering the translation of basic OT research into a much-needed
treatment for social impairments.First, circulating OT does not easily cross the blood-brain bar-
rier (BBB) due to its relatively large molecular weight (McEwen,
2004). Almost all trials have delivered OT intranasally (but see
Hollander et al., 2007, 2003) as OT oral administration is limited by
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ffects of ﬁrst-pass metabolism. However, the mechanisms under-
ying nose-to-brain OT activity are poorly understood (Quintana
t al., 2016), particularly in respect to potential peripheral effects,
equired dosage (Leng and Ludwig, 2016), and the origin (i.e.,
ndogenous vs. exogenous) of observed increases in CSF OT con-
entrations after intranasal administration (Neumann et al., 2013).
hree potential routes have been identiﬁed (Guastella et al., 2013;
uintana et al., 2015a): two direct nose-to-brain pathways and an
ndirect pathway across the BBB via systematically circulating OT.
he direct trigeminal and olfactory nerve ﬁber nose-to-brain path-
ays are purported to deliver OT directly to the brain, however,
ithout a control for peripheral action (e.g., IV administration) it is
nclear if systemically circulating OT plays a role in central effects
Leng and Ludwig, 2016). Assessing the impact of peripheral effects
ia an OT IV comparator would facilitate the comparison of neural
esponse between systemic delivery across the BBB (or stimulation
f peripheral OT receptors) and central delivery using nose-to-
rain pathways. While a poor mechanistic understanding should
ot hinder ongoing investigations into the efﬁcacy of intranasal
T for the potential treatment of psychiatric illness (Quintana and
oolley, 2016), a better conceptualization of intranasal OT deliv-
ry will improve future research by capitalizing on how OT engages
roposed targets. Second, there is an urgent need to establish the
ptimum dose for intranasal OT treatment (Guastella and Hickie,
016; Insel, 2016; Leng and Ludwig, 2016; Yamasue, 2016). The
ost common dose with conventional pump-actuated nasal sprays
24IU) has largely been selected due to precedence, rather than
xperimental evidence (Quintana et al., 2015a). Dose-dependent
ffects of OT on social behavior in animals (Benelli et al., 1995; Popik
t al., 1992) and humans (Cardoso et al., 2013; Hall et al., 2012;
uintana et al., 2015b) that indicate that lower doses of OT may
e more efﬁcacious warrants further research. Speciﬁcally, char-
cterizing the IN-OT dose-response shape is important given the
ide distribution of OT receptors (and cross-reactive AVP recep-
ors) located throughout the body (Gimpl and Fahrenholz, 2001),
hich may  drive potential unintended or even counter-balancing
ffects (e.g., Mayer-Hubner, 1996).
Addressing these obstacles, we recently reported behavioral
ata from a randomized crossover trial in healthy adults comprising
our treatments; 8IU, 24IU and placebo delivered intranasally with
 novel Breath Powered nasal spray device and 1IU intravenous
T – which produced blood plasma OT concentrations compa-
able to 8IU and 24IU intranasal OT (Quintana et al., 2015b). In
omparison with placebo, only the lower 8IU dose was  found to
ttenuate the perception of anger in facial emotion stimuli. As no
uch effects were observed with the intravenous route, despite
quivalent peripheral OT concentrations, this provided behavioral
vidence that OT travels to the brain via nose-to-brain pathways
nd that a lower dose may  be more optimal than the traditional
osage usually administered, at least when delivered with the
ovel device. While these results provide behavioral evidence of
ose-to-brain delivery and optimal response to a lower dose of opti-
ally delivered OT, the neural mechanisms underlying the varied
esponse to OT administered via different delivery pathways, nasal
evices and dosages has yet to be investigated.
To examine the neural correlates of OT’s behavioral and cog-
itive effects, researchers have adopted brain-imaging tools such
s functional magnetic resonance imaging (fMRI). Converging evi-
ence from this ﬁeld suggests the amygdala − a key brain region
or emotion regulation (LeDoux, 2003), processing (Seeley et al.,
007), detection (Ousdal et al., 2008), and vigilance for social cues
cross sensory modalities (Whalen, 2007) − is an important tar-
et of OT administration. Since Kirsch and coworkers’ seminal
eport (Kirsch et al., 2005), the dampening of amygdala activity in
esponse to emotional stimuli is arguably the most replicated and
ell-characterized result within brain imaging and intranasal OTocrinology 69 (2016) 180–188 181
studies (e.g., Domes et al., 2007; Labuschagne et al., 2010; Petrovic
et al., 2008; see Domes et al., 2010; Lischke et al., 2012 for opposite
effects in females, and Meyer-Lindenberg et al., 2011; Bethlehem
et al., 2013 for comprehensive reviews). By comparing amygdala
activity after both intranasal and intravenous OT administration,
when comparable blood levels are achieved, research can better
determine if the reported neural modulation occurs via direct nose-
to-brain transport (as currently assumed) or through systemically
circulating OT crossing the BBB. There is both animal (Popik et al.,
1992) and human (Hollander et al., 2007, 2003) research to suggest
systemic OT can inﬂuence social behavior and cognition − however,
research has not yet evaluated amygdala activity after intravenous
delivery with an intranasal OT comparator.
To better understand the delivery routes of intranasal OT
administration to the brain and the dose-response, this ran-
domized, double-blind, double-dummy, 4-way crossover trial in
healthy volunteers compared amygdala activity during emotional
face processing between four treatment groups: “low dose” (8IU)
OT delivered with a Breath Powered OptiNose device (OPN-OT),
“higher dose” (24IU) OPN-OT, OT delivered intravenously (IV; 1IU),
and placebo (Quintana et al., 2015b). It was hypothesized that OT
administration would reduce amygdala activity, with a stronger
effect after low dose administration. Modulation of amygdala acti-
vation after OPN-OT administration, but not after IV-OT producing
comparable blood exposure, would provide evidence that OPN-OT
is directly acting on the brain via deep nasal cavity pathways rather
than by entry into the systemic circulation and subsequent travel
across the BBB.
2. Materials and methods
2.1. Participants
Participants were recruited through advertisements at the Uni-
versity of Oslo, and were eligible to participate if male, aged
18–35 (inclusive), and in good physical and mental health. Exclu-
sion criteria included use of any medications within the last 14
days, history of alcohol or drug abuse, and IQ <75. A screen-
ing visit occurred between 3 and 21 days prior to randomization
at Oslo University Hospital. The Wechsler Abbreviated Scale of
Intelligence (Wechsler, 1999) and the Mini-International Neu-
ropsychiatric Interview (Lecrubier et al., 1997) were administered
by trained graduate students under the supervision of study physi-
cians and clinical psychologists to index IQ and conﬁrm the absence
of psychiatric illness, respectively. To rule out somatic illnesses,
a physical examination was  performed by study physicians and
nurses, which included a 12-lead ECG and the collection of blood
samples to assess routine hematology and chemistry measures.
An otolaryngologist conﬁrmed normal nasal anatomy and patency
in participants via physical examination consistent with recent
recommendations (Guastella et al., 2013) and acoustic rhinom-
etry (AR) data were collected by trained study staff under the
supervision of an otolaryngologist (SRE 2000; Rhinometrics, Lynge,
Denmark). This trial was  approved by the Regional Committee for
Medical and Health Research Ethics (REC South East) and partici-
pants provided written informed consent in accordance with the
Declaration of Helsinki before they participated (see also Quintana
et al., 2015b). The study is registered at http://clinicaltrials.gov
(NCT01983514) and as EudraCT no. 2013-001608-12.
2.2. Study designParticipants received 8IU OPN-OT intranasally, 24IU OPN-OT
intranasally, OT delivered intravenously (1IU), and placebo in
a randomized, placebo-controlled, double-blind, double-dummy,
182 D.S. Quintana et al. / Psychoneuroendocrinology 69 (2016) 180–188
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ode.  Note that the tip of the nosepiece used in the present trial is slightly more el
our-period crossover design. Participants were randomized to one
f four treatment sequences, using a four-period four-treatment
atin square method (ACDB–BDCA–CBAD–DABC in a 4:4:4:4 ratio).
n independent statistician (Smerud Medical Research Interna-
ional AS, Oslo, Norway) provided the randomization code, and
oth the participants and research team were blinded to treat-
ent using visually matching devices and IV apparatus during data
ollection. A certiﬁed GMP  manufacturer (Sigma-Tau Industrie Far-
aceutiche Riunite S.p.A., Rome, Italy) provided the OT and placebo
ormulations to a pharmaceutical service provider (Farma Holding
S, Oslo, Norway) for the ﬁlling of the drug and placebo formula-
ions into the OPN-OT devices. The placebo formulation contained
ll excipients except the active ingredient. More details regarding
ntranasal spray ingredients and administration regime are avail-
ble in the Supplementary Material. The IV-OT (0.1 ml  drawn from
 1 ml  ampoule with a 10 IU/ml dose; AS Grindeks, Riga, Latvia) and
lacebo formulations (0.1 ml  0.9% sodium chloride) were added to
 0.9% sodium chloride solution for infusion shortly before admin-
stration (200 ml  over 20 min). The IV-OT dosage and infusion rate
as chosen as it generates peripheral OT concentrations that are
quivalent to OPN-OT, as determined by a pilot pharmacokinetic
tudy and conﬁrmed by the subsequent experimental study (for
ore details regarding solution ingredients and the determination
f the IV-OT infusion rate, see Quintana et al., 2015b). In a double-
ummy  procedure, all participants self-administered an intranasal
reatment using the Breath Powered device and also received an
V solution – either OT or placebo depending on randomization
 in all treatment periods (Fig. 1). A pragmatic approach guided
y prior fMRI OT research (Domes et al., 2007, 2010; Kirsch et al.,
005; Lischke et al., 2012) was taken for sample size determination
eﬂecting the phase 1 status of OT administration using the Breath
owered device and the complex nature of the study design.
.3. Breath Powered delivery device and OT administration
The breath powered, closed-palate, bi-directional nasal spray
“Breath Powered”) device capitalizes on two aspects of nasal
natomy to facilitate efﬁcient posterior and superior delivery of
edication in the nasal cavity (Djupesland, 2012). Firstly, as the
ser is blowing through the mouth against a resistance the soft
alate automatically closes, isolating the nasal cavity from the
ral cavity, preventing lung deposition and limiting gastrointesti-
al deposition (Djupesland et al., 2014). Secondly, an optimized
ealing nosepiece directs the exhaled breath and OT into upper-
osterior nasal cavity segments where, with a closed soft palate,
irﬂow enters via one nostril, expanding the nasal valve and the
arrow slit-line nasal passages, carrying the drug particles to the
arget sites before exiting by the other nostril (i.e., Bi-Directional
elivery; also see Quintana et al., 2015b for more detail). This deliv-
ry mechanism has been shown to improve deposition of drug at
ntranasal sites beyond the nasal valve and notably to target regions each treatment condition to blind participant and experimenter to administration
ed than the tip shown in the ﬁgure.
in the upper and posterior nasal cavity (Djupesland, 2012), and non-
bioequivalent therapeutic (Dale et al., 2006) and pharmacokinetic
(Obaidi et al., 2013) outcomes compared to traditional nasal spray
devices. The Breath Powered device has been previously used to
administer other therapeutics, including sumatriptan (Tepper et al.,
2015) and an inﬂuenza vaccine (Bakke et al., 2006).
2.4. Outcome measures
The primary imaging outcome measure was  amygdala acti-
vation in response to the presentation of emotional stimuli. The
social cognition task and fMRI sequence began 40 min  after treat-
ment administration, lasting 21 min  (Fig. 2). Participants were
presented with visual stimuli through MRI-compatible goggles
(VisualSystem; NordicNeuroLab, Bergen, Norway) using E-Prime
2.0 (Psychology Software Tools, PA, USA) and responded using a
grip response collection system (ResponseGrip, NordicNeuroLab,
Bergen, Norway).
In an event-related design, participants were presented with
pseudo-randomized 20 male and 20 female faces (as used previ-
ously; Leknes et al., 2012; Quintana et al., 2015b) displaying angry,
happy and emotionally ambiguous (i.e., neutral) facial expressions
(derived from the Karolinska Directed Emotional Faces database;
Lundqvist et al., 1998) and 20 images of geometrical shapes for
each treatment condition. The social cognition task consisted of ﬁve
blocks of 20 trials (Fig. 2). Each trial of approximately 140 s duration
comprised the following sequence: Fixation cross of 3 s dura-
tion ≥ Stimulus (face/shapes) presentation of 1 s duration ≥ Q1 of
3.25 s duration (maximum response window) ≥ Q2 of 3.25 s dura-
tion (maximum response window). There was jittering at the end
of each sequence to account for participants responding before the
end of the 3.25 s response windows in order to make the sequence
times equivalent. In Q1, regardless of facial expression, partici-
pants were asked either: How angry is this person? (anchors: not
angry—very angry) or How happy is this person? (anchors: not
happy—very happy). Q2 was always the same: How much would
you trust this person? (anchors: not at all—very much). For the
shapes, participants were asked either: (Q1) How yellow is this
shape? (anchors: not yellow—very yellow) or How blue is this
shape? (anchors: not yellow—very yellow). Q2 was always: How
much do you like this color? (anchors: not at all—very much). Par-
ticipants were asked to rank their answer on a numerical rating
scale (NRS) from 1 to 5, with initial location of the cursor on the
NRS randomized for each question.
2.5. MRI  acquisitionBrain imaging data was  collected on a 3T General Electric
Signa HDxt scanner with an 8-channel head coil (GE Health-
care, Milwaukee, WI,  USA). The protocol included a T2*-weighted
gradient echo-planar imaging (EPI) sequence acquired in the
D.S. Quintana et al. / Psychoneuroendocrinology 69 (2016) 180–188 183
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eig. 2. Social-cognitive task design. Using a double-dummy design, participants wer
he  end of this 20-min period. The contents of the IV and intranasal solutions differed
ompletion. Resting state MRI  was acquired but not analyzed for the present paper
ransverse plane with the following parameters: Repetition time
TR) = 2400 ms,  echo time (TE) = 30 ms,  ﬂip angle (FA) = 90◦, 64 × 64
atrix. One run of 528 volumes was collected for each individ-
al in each treatment condition (48 slices; in-plane resolution
.75 × 3.75 mm;  slice thickness 3.2 mm,  no gap). A T1-weighted
olume used for co-registration purposes was acquired using a
agittal fast spoiled gradient echo (FSPGR) sequence with the fol-
owing parameters: TR = 7.8 ms,  TE = 2.9 ms,  ﬂip angle = 12◦, 166
lices; in-plane resolution: 1 × 1, slice thickness: 1.2 mm,  256 × 256
atrix.
.6. MRI  analysis
FreeSurfer (http://surfer.nmr.mgh.harvard.edu) was used for
he analysis of T1-weighted data, including surface reconstruction
nd full brain segmentation (Fischl et al., 2002) to obtain pre-
ise brain extracted volumes for co-registration of the fMRI data.
MRIB Software Library (FSL; http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/;
enkinson et al., 2002) was used to process fMRI data. The ﬁrst
ve volumes were discarded. Pre-processing of fMRI data was
onducted using FMRIB’s Expert Analysis Tool (FEAT) version 6.0
Smith et al., 2004). This included motion correction using MCFLIRT
Jenkinson et al., 2002), spatial smoothing by means of SUSAN
Smith and Brady, 1997) using a Gaussian kernel of FWHM of
 mm,  and a temporal high pass ﬁlter of 100 s. FMRIB’s Linear
nd non-linear Image Registration Tools (FLIRT; Jenkinson et al.,
002) optimized using Boundary Based Registration (BBR; Greve
nd Fischl, 2009) was used to align each participant’s fMRI data to
 standard space (MNI-152) with the T1-weighted volume as an
ntermediate.
We ﬁtted individual level general linear models (GLM) using
ILM (FMRIB’s Improved Linear Model; Smith et al., 2004; Woolrich
t al., 2001) modeling the facial stimuli (happy/angry/ambiguousinistered an IV solution over 20 min and self-administered an intranasal solution at
rding to treatment condition. The social cognitive task began 40 min  after treatment
ursor starting position for ratings was  randomized.
faces) and geometrical shape as events with the interspersed ﬁx-
ation trials as implicit baselines. Q1 and Q2 were modeled as one
regressor across the different facial stimuli and shapes. Individual
explanatory variables (EVs) for the Q phase of each trial were mod-
eled across the emotion-conditions to account for variance related
to the response phase in the fMRI data, but we  did not test for
effects of OT treatment on this EV. Next, we  extracted the aver-
age amygdala contrast-parameter estimates (COPE) from left and
right amygdala masks based on the Harvard-Oxford anatomical
atlas provided with FSL and submitted the values to higher-level
linear mixed models in SPSS to test for main effects of condition
and treatment (see below).
2.7. Pharmacokinetics
Methods describing blood plasma collection and analysis of
OT, arginine vasopressin (AVP), and cortisol concentrations over
the course of the testing session have been previously reported
(Quintana et al., 2015b). In brief, blood samples were collected
via IV catheter to assess peripheral levels of OT, AVP, and cortisol
at baseline and ﬁve time points after the completion of treat-
ment administration (0 min, 10 min, 30 min, 60 min, and 120 min)
throughout the session. Blood samples were centrifuged at 4 ◦C
within 5 min  of blood draw, after which plasma was  frozen at
−80 ◦C until enzyme-linked immunosorbent assay (ELISA) using
commercially available kits (Enzo Life Sciences, Farmingdale, NY)
was performed by the Oslo University Hospital hormone laboratory
using standard techniques (including sample extraction).2.8. Statistical analysis
Statistical analysis was  conducted using IBM SPSS Statistics ver-
sion 22 (IBM, Armonk, N.Y) to examine the impact of treatment on
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mygdala activation. As per previous work (Quintana et al., 2015b),
 linear mixed-model (LMM)  approach was adopted for the analysis
f amygdala activity. All models were ﬁtted using an unstructured
atrix. Experimental treatment was both a ﬁxed and repeated
ffect in the LMM  testing the impact of treatment on amygdala
ctivity. The same LMM approach was used to examine differences
n COPE values for contrasts of both left and right amygdala activity
etween angry faces and shapes, happy faces and shapes, and happy
aces and angry faces. Standardized residuals after model ﬁtting
ere examined for outliers, and Z-scores above 2.58 or below −2.58
ere removed from the analysis. Outliers beyond these thresholds
ere removed from the amygdala activation datasets (1 value from
he right amygdala data during the presentation of angry, happy
nd, ambiguous, and shape stimuli, respectively; 1 value from left
mygdala anger and happy data, respectively; and 2 values from
he left amygdala ambiguous and shape data, respectively). Post-
oc tests were performed to compare each treatment condition,
ith the adjustment of critical p values to correct for multiple
omparisons using a 5% false discovery rate (FDR; Benjamini and
ochberg, 1995). The relationships between amygdala activation
nd behavioral ratings, and nasal physiology, respectively, were
lso assessed for any signiﬁcant main effects. Finally, Bayes Factors
sing the Jeffreys-Zellner-Siow prior (Wetzels and Wagenmakers,
012) were calculated to examine the strength of evidence for both
he null and alternative hypotheses. To investigate the impact of
reatment on blood plasma concentration of OT (as described in
uintana et al., 2015b) an LMM  was ﬁtted with three ﬁxed fac-
ors (treatment, time, treatment × time) and one repeated factor
treatment).
. Results
Fifty-seven male volunteers were assessed for eligibility, and
8 participants aged 20–30 years (M = 23.81, SD = 3.33) were ran-
omized (Supplementary Fig. S1). On average, eight days elapsed
etween each treatment session (range: 6–20 days, SD = 3.5 days).
wo participants withdrew after enrollment [1 withdrew after the
rst session (Placebo) and the other withdrew after completing
hree sessions (8IU OPN-OT, IV-OT, Placebo)]. Data from these par-
icipants are not included in the analyses. Recruitment commenced
eptember 2013 and the last data were collected February 2014.
LMM revealed a signiﬁcant main effect of treatment on
ight amygdala activation during the presentation of angry faces
F(3,15.1) = 4.54, p = .019; Figs. 3A and Fig. 4]. Follow-up pairwise
omparisons (q = .05, revised threshold value of p = .008) indicated
hat right amygdala activation was signiﬁcantly reduced in the 8IU
PN-OT treatment condition in comparison to placebo (p = .002).
here was a main effect of treatment on right amygdala activity in
esponse to the presentation of happy faces [F(3,15) = 3.44, p = .04;
igs. 3B and Fig. 4], however, posthoc comparisons indicated the
eduction after 8IU OPN-OT compared to placebo was  not statis-
ically signiﬁcant after multiple comparison threshold correction
p = 0.01; q = .05; revised threshold value of p = .008). There was
o main effect of treatment for right amygdala activity during the
resentation of ambiguous faces [F(3,14.6) = 3.15, p = .057; Figs. 3C
nd Fig. 4]. Exploratory posthoc analyses revealed the reduction
f right amygdala activity after 8IU OPN-OT treatment compared
o placebo did not survive the FDR corrected signiﬁcance thresh-
ld (p = 0.01; q = .05; revised threshold value of p = .008). There was
lso a main effect of treatment on right amygdala activation during
he presentation of geometric shapes [F(3,15) = 3.56, p = .04; Figs.
D and Fig. 4], however, post hoc analyses revealed no signiﬁcant
ifferences after FDR corrected thresholds. There was a main effect
or the happy faces > angry faces contrast for the right amygdalaocrinology 69 (2016) 180–188
[F(3,14.7) = 4.46, p = .02] but no posthoc comparisons survived FDR
corrected thresholds.
In regards to left amygdala activity, a LMM  revealed no
main effect of treatment during the presentation of angry
faces [F(3,15.1) = 1.28, p = .32], ambiguous faces [F(3,13.6) = 1.14,
p = .37], happy faces [F(3,14) = 2.14, p = .14], or geometric shapes
[F(3,14.4) = 1.87, p = .18; Fig. 4]. There was a main effect for
the happy faces > angry faces contrast on left amygdala activity
[F(3,14.7) = 4.79, p = .02], but no posthoc comparisons survived FDR
corrected thresholds. The main effect of task (i.e., brain reactivity
across stimuli types and treatments) is presented in Supplementary
Fig. S2. There were no main effects of treatment for any of the emo-
tion > shape COPE value contrasts (Supplementary Table 1). Finally,
there were no signiﬁcant relationships between intensity of anger
ratings and right amygdala activations after any of the treatments
(Supplementary Table 2), or between nasal valve dimensions and
right amygdala activation after any of the treatments (Supplemen-
tary Table 3). Plasma OT concentration was signiﬁcantly increased
in all active treatment conditions, with none of the pairwise com-
parisons between active conditions reaching statistical signiﬁcance
(see Supplementary Material Text and Fig. S3). The frequency
of adverse events (e.g., brief dizziness) reported was equivalent
between treatment groups (8IU OPT-OT, three reports; 24IU OPT-
OT, two  reports, IV OT, three reports, placebo, two reports).
4. Discussion
In this double-blind, placebo controlled crossover trial in
healthy volunteers, we  show that 8IU OPN-OT treatment reduces
amygdala activation in response to emotional faces compared to
placebo. These ﬁndings are the ﬁrst to report direct comparison
of intranasal delivery to systemic delivery of OT. Results indicate
that the tested type of intranasal OT delivery – but not peripherally
delivered OT that produces similar blood levels – replicates prior
ﬁndings of reduced right amygdala activation in response to emo-
tional stimuli after OT treatment (Domes et al., 2007; Labuschagne
et al., 2010; Petrovic et al., 2008). The data are also consistent with
recently reported results from the same experiment suggesting that
a low dose of OT delivered by a Breath Powered device modulates
the perception of anger in neutral facial stimuli (Quintana et al.,
2015b). Furthermore, the data are in line with animal research that
has associated a lower OT dose with stronger increases in social
recognition (Benelli et al., 1995; Popik et al., 1992), which is perti-
nent given the crucial role of the amygdala in social cognition and
behavior.
These effects may  not be speciﬁc to negatively valenced social
stimuli as the main effect of treatment on right amygdala activity
during the presentation of happy faces was also statistically signif-
icant, with subsequent posthoc comparisons revealing a reduction
of activity after 8IU OPN-OT treatment compared to placebo
(however this difference fell short of signiﬁcance after multiple
comparison threshold adjustment). The observed reductions in
right amygdala activation during the presentation of both nega-
tively and positively valenced stimuli after intranasal OT treatment
and the additional main effect of treatment on amygdala reactivity
to shapes – which did not reveal any posthoc differences between
groups but were in the same direction as the other analyses – are
consistent with the hypothesis that intranasal OT  delivery has two
levels of action (Quintana et al., 2015a); a bottom-up effect that
facilitates approach-related behaviors (Kemp and Guastella, 2011)
and a top-down effect which increases the social salience of stimuli,
regardless of emotional valence (Bartz et al., 2011). OT’s dampen-
ing effect on amygdala activity, regardless of emotional valence,
may  underlie reported improvements in social behavior (Yatawara
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Fig. 3. Right amygdala activity in response to faces. Right amygdala activity (z-scores) during the presentation of angry faces (A), happy faces (B), ambiguous faces (C), and
shapes (D). Right amygdala activity was reduced after the administration of 8 IU OPN-OT in comparison with placebo during the presentation of angry faces (A). Violin plots
illustrate the distribution of the z-score normalized data by showing the probability density of the data at different values (plot tails trimmed to the range of data) with
means  and standard errors. *p = 0.002 (q = .05, revised FDR threshold value of p = .008).
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n  parentheses. Cell colors also represent z-score normalized means. **<0.008 (FDR
t al., 2015) and cognition (Davis et al., 2013; Guastella et al., 2010)
fter IN OT via these two levels of action.
There is a high density of OT receptors in the amygdala (Insel
nd Shapiro, 1992; but see Freeman et al., 2014). These receptors
ave been shown to operate by inhibiting amygdala activity via
he increase of GABAergic interneuron activity (Knobloch et al.,
012). The observed decrease in amygdala activity after Breath
owered intranasal OT administration is consistent with nose-to-
rain molecule transport via olfactory and trigeminal nerve ﬁber
athways (Thorne et al., 2004). The olfactory bulbs and brainstem
re the two ﬁrst central destinations for intranasal OT delivery
Quintana et al., 2015a). Outputs to the amygdala via the olfactory
ulbs (Sosulski et al., 2012) or transport through brain extracellu-
ar ﬂuid (Neumann et al., 2013) from olfactory bulb and brainstem
elivery sites after intranasal delivery may  facilitate these reduc-mygdala activity values represent z-score normalized means with standard errors
ted threshold value), *<0.05.
tions in amygdala activity via a local GABAergic circuit. IV-OT
administration can plausibly inﬂuence central activity through the
stimulation of peripheral OT receptors (Leng and Ludwig, 2016) or
via small amounts of OT crossing the BBB (Neumann et al., 2013).
As IV-OT treatment, which produced comparable levels of systemic
OT exposure with IN-OT administration, did not modulate amyg-
dala activity compared to placebo, this study demonstrates that
nose-to-brain pathways produce neural effects, suggesting facili-
tated entry to, or activity in, the brain with at least this form of
intranasal delivery. The dose-response data reported here suggest
that a low dose of OT delivered using a Breath Powered device is
sufﬁcient to dampen amygdala activity. There was no signiﬁcant
relationship between anger ratings and amygdala activity, which
indicates that a larger neural network that goes beyond the amyg-
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ala likely underlies the effect of OT on social cognition (Bethlehem
t al., 2013).
There are a number of reasons that may  explain why an effect
as found with the 8IU dose but not the 24IU dose. First, cross
eactivity with AVP receptors may  offset the activation of OT recep-
ors (Neumann and Landgraf, 2012) and heighten reactivity of the
ypothalamic-pituitary-adrenal axis (Legros, 2001). It is also pos-
ible that an 8IU dose delivered with the Breath Powered device is
etter able to reach the regions in the nose where direct nose-to-
rain transport can occur due to the device expanding the narrow
asal valve and targeting molecule delivery to target regions in
he upper and posterior nasal cavity. Of note, other studies have
eported similar results after administration of 24 IU (Domes et al.,
007; Kanat et al., 2015; Labuschagne et al., 2010), however, the
osages are difﬁcult to compare between experiments as these
tudies used traditional nasal spray devices to administer OT. We
ound no evidence that 1 IU of peripherally administered OT inﬂu-
nces amygdala activity. While there is conﬂicting evidence on
hether peripheral OT can cross the BBB (Modi et al., 2014), our
tudy suggests that even if OT does travel across this barrier in small
mounts, this quantity is not large enough to dampen amygdala
ctivity compared to placebo.
Although the study recruited a similar number of participants
onsistent with prior OT fMRI research, the sample size was  still
elatively small necessitating the need for future studies to adopt
arger sample sizes, which would provide more robust outcomes
s small samples sizes may  inﬂate the issue of spurious ﬁndings in
xytocin research (Lane et al., 2016; Leng and Ludwig, 2016). The
resent study design also did not include a comparison between
he Breath Powered device and a traditional nasal spray device.
hile this is of interest for future research, the focus for this study
as to compare systemic vs. intranasal administration. Including a
raditional nasal spray device would necessitate the inclusion of an
dditional OT and placebo arm and also double the volume of liquid
or intranasal administration, thus increasing the chances of liquid
oss by anterior drip-out and/or down the esophagus. It has been
eported the nasal cavity can only accommodate about 100 l of
iquid per nostril (Merkus et al., 2003) and a double-dummy design
ould increase the volume to an unacceptable level. Since the gen-
ralizability of these results are limited to healthy males, future
ork is needed to investigate neural responses after intranasal OT
dministration in healthy females as well as psychiatric popula-
ions characterized by social impairments (e.g., ASD). Individual
ifferences and context can inﬂuence the response to OT admin-
stration (Bartz et al., 2011), thus a strength of this study was  the
se of a within-subjects design in a homogenous sample to examine
mygdala activity. By adopting this experimental design, any indi-
idual differences due to variation in the endogenous OT system
Gouin et al., 2010) are minimized.
In summary, we present new knowledge in relation to an
mproved method of deep intranasal OT delivery. Speciﬁcally, we
how that low dose intranasal OT delivered with a Breath Pow-
red device dampens amygdala activity. We  present the ﬁrst data
o evaluate neural activity after different intranasal OT doses, in
ddition to an IV OT administration arm to control for peripheral
ffects. This result provides additional evidence to suggest a lower
ntranasal OT dose may  better facilitate the modulation of social
ognition and behavior and that peripheral actions of OT do not
ppear to have any signiﬁcant neural corollaries.
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